Robert J. Grun

Array ( [id] => 20729119 [patent_doc_number] => 12636363 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-26 [patent_title] => Anti-transferrin receptor fusion proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 19/304112 [patent_app_country] => US [patent_app_date] => 2025-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 20110 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19304112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20511314 [patent_doc_number] => 20260035415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-05 [patent_title] => HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/287483 [patent_app_country] => US [patent_app_date] => 2025-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19287483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20568566 [patent_doc_number] => 20260062487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-05 [patent_title] => MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/284186 [patent_app_country] => US [patent_app_date] => 2025-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19284186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20050191 [patent_doc_number] => 20250188413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-12 [patent_title] => TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES [patent_app_type] => utility [patent_app_number] => 19/011427 [patent_app_country] => US [patent_app_date] => 2025-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 140864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19011427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20187102 [patent_doc_number] => 12398207 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Heterodimeric antibodies that bind CD3 and CLDN6 [patent_app_type] => utility [patent_app_number] => 18/810362 [patent_app_country] => US [patent_app_date] => 2024-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 137 [patent_figures_cnt] => 190 [patent_no_of_words] => 39392 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18810362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20200437 [patent_doc_number] => 12403202 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Dosage of claudin-6 conjugates for cancer treatment [patent_app_type] => utility [patent_app_number] => 18/674612 [patent_app_country] => US [patent_app_date] => 2024-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 8 [patent_no_of_words] => 27233 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18674612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667569 [patent_doc_number] => 12180297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => ATP-dependent agonists of immune cells function as anticancer agents [patent_app_type] => utility [patent_app_number] => 18/593028 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 14 [patent_no_of_words] => 26812 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232214 [patent_doc_number] => 20240189405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => DNA Monoclonal Antibodies Targeting Checkpoint Molecules [patent_app_type] => utility [patent_app_number] => 18/413721 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380942 [patent_doc_number] => 20240270812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES [patent_app_type] => utility [patent_app_number] => 18/405839 [patent_app_country] => US [patent_app_date] => 2024-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18405839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316876 [patent_doc_number] => 20240238416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS [patent_app_type] => utility [patent_app_number] => 18/531312 [patent_app_country] => US [patent_app_date] => 2023-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067277 [patent_doc_number] => 20240101703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 [patent_app_type] => utility [patent_app_number] => 18/520264 [patent_app_country] => US [patent_app_date] => 2023-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18520264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216281 [patent_doc_number] => 20240180985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => FOOD AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FATTY LIVER AND INFLAMMATION BY RELIEVING ENDOPLASMIC RETICULUM STRESS [patent_app_type] => utility [patent_app_number] => 18/519482 [patent_app_country] => US [patent_app_date] => 2023-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18519482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332645 [patent_doc_number] => 20240247075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/505660 [patent_app_country] => US [patent_app_date] => 2023-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233774 [patent_doc_number] => 20240190966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => ANTI-LY6G6D ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/504041 [patent_app_country] => US [patent_app_date] => 2023-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034184 [patent_doc_number] => 20240083999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/501648 [patent_app_country] => US [patent_app_date] => 2023-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19090924 [patent_doc_number] => 11952354 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-09 [patent_title] => 5-((2-isopropyl-5-methylphenoxy)methyl)-3-(naphthalen-2-yl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/386421 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4472 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034200 [patent_doc_number] => 20240084015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4 [patent_app_type] => utility [patent_app_number] => 18/499658 [patent_app_country] => US [patent_app_date] => 2023-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20179543 [patent_doc_number] => 20250263501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => MONOCLONAL ANTIBODY USED FOR DIAGNOSIS AND EARLY ONSET OF PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 18/992587 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18992587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923002 [patent_doc_number] => 20240026006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-GPC3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/366930 [patent_app_country] => US [patent_app_date] => 2023-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18366930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157752 [patent_doc_number] => 20240150459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => Anti-LAG-3 Antibodies to Treat Hematological Malignancies [patent_app_type] => utility [patent_app_number] => 18/227636 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18227636 [rel_patent_id] =>[rel_patent_doc_number] =>)